Dimensional Fund Advisors LP Acquires 34,512 Shares of SI-BONE, Inc. (NASDAQ:SIBN)

Dimensional Fund Advisors LP boosted its position in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 10.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 354,835 shares of the company's stock after acquiring an additional 34,512 shares during the period. Dimensional Fund Advisors LP owned 0.85% of SI-BONE worth $4,974,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Barclays PLC raised its position in shares of SI-BONE by 190.8% during the 3rd quarter. Barclays PLC now owns 96,623 shares of the company's stock valued at $1,350,000 after buying an additional 63,402 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of SI-BONE by 14.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 177,793 shares of the company's stock valued at $2,486,000 after purchasing an additional 22,732 shares in the last quarter. R Squared Ltd bought a new stake in shares of SI-BONE during the 4th quarter valued at about $73,000. Legato Capital Management LLC boosted its stake in shares of SI-BONE by 9.1% during the 4th quarter. Legato Capital Management LLC now owns 62,707 shares of the company's stock valued at $879,000 after purchasing an additional 5,209 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in SI-BONE by 3.0% during the fourth quarter. Rhumbline Advisers now owns 57,621 shares of the company's stock worth $808,000 after acquiring an additional 1,683 shares in the last quarter. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Anshul Maheshwari sold 4,937 shares of the firm's stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $19.02, for a total value of $93,901.74. Following the completion of the sale, the chief financial officer now owns 232,069 shares in the company, valued at approximately $4,413,952.38. This trade represents a 2.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Laura Francis sold 38,504 shares of the firm's stock in a transaction dated Wednesday, May 7th. The stock was sold at an average price of $17.18, for a total transaction of $661,498.72. Following the completion of the sale, the chief executive officer now owns 302,958 shares of the company's stock, valued at $5,204,818.44. This trade represents a 11.28% decrease in their position. The disclosure for this sale can be found here. Insiders sold 55,153 shares of company stock valued at $935,040 in the last three months. Corporate insiders own 4.00% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SIBN. Needham & Company LLC reissued a "buy" rating and set a $24.00 price objective on shares of SI-BONE in a research note on Tuesday, May 6th. Truist Financial boosted their price objective on shares of SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a report on Tuesday, May 6th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 target price on shares of SI-BONE in a report on Tuesday, May 6th.

SI-BONE Price Performance

Shares of SIBN traded up $0.91 during mid-day trading on Friday, reaching $19.79. The stock had a trading volume of 795,534 shares, compared to its average volume of 373,959. The firm has a market cap of $843.35 million, a price-to-earnings ratio of -21.51 and a beta of 0.82. SI-BONE, Inc. has a 12 month low of $11.70 and a 12 month high of $20.05. The business has a fifty day moving average of $14.83 and a 200 day moving average of $15.04. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25.

SI-BONE (NASDAQ:SIBN - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.09. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The firm had revenue of $47.29 million during the quarter, compared to analyst estimates of $45.13 million. Equities analysts predict that SI-BONE, Inc. will post -0.78 EPS for the current year.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.